Thursday 31 December 2020
Wednesday 30 December 2020
Investor Ideas #Potcasts 511, #Cannabis News and #Stocks on the Move; #Psychedelic Spotlight (OTCQB: $ALID) (CSE: $PULL.C) (CSE: $NOVA.C)
Investor Ideas #Potcasts 511, #Cannabis
News and #Stocks on the Move; #Psychedelic Spotlight (OTCQB: $ALID) (CSE: $PULL.C)
(CSE: $NOVA.C)
Delta, Kelowna, BC, December 30, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/123020-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/12301ALID-PULL-NOVA.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few private and public company
announcements, specifically focussing on the psychedelic sector.
SYNTAC
Institute,
an Alberta-based non-profit organization dedicated to bringing legal
psychedelic-assisted therapy to Canadians, recently
confirmed that it has facilitated the first announced approval
from Health Canada for an Alberta-based patient facing a terminal illness
diagnosis.
The legal exemption from the
Canadian Drugs and Substances Act, granted by the Office of Controlled
Substances at Health Canada, paves the way for Calgary resident Anthony White
to immediately undergo psilocybin-assisted treatment to deal with the severe
mental health challenges that come with a terminal medical diagnosis. White's situation has been even more
difficult to contend with as he is in his forties and has a young daughter.
Under the Section 56 Exemption
approved by Health Canada, White will now be eligible to participate in a
therapy process overseen by a medical team that includes the use of psilocybin,
an active hallucinogenic substance found in "magic mushrooms".
"Facing this devastating
prognosis has been incredibly difficult, but I am grateful I can soon gain some
comfort and relief through this promising therapy. I appreciate the help from the folks at
SYNTAC to bring this to reality, and to Health Canada for putting the patient
first in this important decision."
Encouraging research continues to
emerge that suggests psychedelic-assisted therapeutic approaches to mental and
emotional health conditions demonstrate remarkable efficacy and outcomes for a
variety of conditions including end-of-life distress, Post Traumatic Stress
Disorder (PTSD), depression and anxiety.
"We are extremely grateful to
Health Canada and the Hon. Minister Hajdu and her team for delivering this
exemption so that Mr. White can immediately access this innovative
therapy," stated David Harder, Executive Director of SYNTAC Institute in
Calgary.
"We are also deeply
appreciative of the tireless efforts of Dr. Bruce Tobin and his team at
Therapsil in Victoria B.C. for putting in so much of the groundwork required
for this kind of announcement to be possible."
With the traditional approach to
mental health and wellness in Canada already struggling, COVID-19 is creating a
tsunami of mental and emotional health challenges that threaten to overwhelm
the Canadian healthcare system. "We
believe psychedelic medicines will be a huge part of the solution that
Canadians need and deserve", added Harder.
"We are not only incredibly
thrilled for Mr. White gaining immediate access to this powerful therapeutic
tool, but also for every Canadian who is suffering with mental and emotional
health challenges. This is another step
forward in the battle against our country's mental health crisis."
Allied Corp (OTCQB:
ALID) – an international medical cannabis company focused
on creating and providing health solutions to address today’s medical mental
health issues, recently
announced the signing of a letter of intent to acquire the
psilocybin company Pacific Sun Fungi. This further expands upon Allied’s press
release of October 20, 2020 communicating the submission of the provisional
patent for Allied’s functional mushroom formulation targeting major depression
and anxiety.
Pacific
Sun is a British Columbia corporation that has been working on Research and
Development activities in the psilocybin space for the past 10 years. Pacific
Sun holds several formulations that have been tested under physician
supervision. Pacific Sun also has proprietary extraction technology,
proprietary formulations for several specific disease targets and physician-led
therapy protocols that have proven to be effective for several specific disease
targets.
Over the
past two years, in parallel with psilocybin moving into the pharmaceutical
research realm, Allied has continued to develop its pharmaceutical research
infrastructure. This represents the evolution of Allied beyond specific
cannabis-based therapies to more pharma-based health targets.
Allied
was born out of the need to support veterans and first responders suffering
from PTSD with targeted cannabinoid solutions. This acquisition has advanced
Allied into the broader mental health market encompassing both pharmaceutical
and natural health products. Building upon our experience with PTSD, we are
expanding our research and treatment options to encompass depression, anxiety
and general mental health. This puts Allied in the unique position to provide a
full-scope, closed-loop therapy protocol. Typical psilocybin therapies support
the patient for an episodic micro-dosing treatment regime which follows a
specific dosing and wash out cycle. Unfortunately, this leaves the patient with
a treatment gap between dosing periods. This can now be bridged with Allied’s
existing cannabinoid treatment solutions. A “full scope treatment” option.
The proprietary
“Allied full scope treatment” offers
the patient continual therapy with treatment options both before and after the
psilocybin treatment period. This is accomplished by offering Allied’s
cannabinoid and natural health products combined with the psilocybin products
and protocols. This will all be accomplished under legal license and physician
supervision.
A
timeline leading towards Allied as being positioned as a leader in this space:
● In 2018,
the FDA recognized psilocybin therapies as a “breakthrough” therapy for PTSD
and Major Depressive Disorder. (Food and
Drug Administration, 2018).
●
In 2019, Imperial College of London and
John Hopkins open the first psychedelic research centers. MAPS clinics across
the nation conduct research on psilocybin therapy. (Forbes.com, 2019).
●
In 2020, Health Canada approves psilocybin
for select patient with terminal illness. 2020 Oregon State decriminalizes
psilocybin. On November 30, 2020 Oregon state issues call for participants in
State Guidance Committee. Allied executive applies to be a member of this
committee. (Health Canada, 2020 and
Oregon State Health, 2020).
●
On October 20, 2020, Allied submits
provisional patent on drug formulation containing psilocybin and a combination
of additional functional mushrooms for the disease targets of PTSD, depression
and general anxiety. (Allied Corp press
release of Oct 20, 2020).
● On
December 20th, 2020, Allied moves to acquire Pacific Sun Fungi by
signing Letter of Intent to acquire.
Allied’s
initial focus will be on pharmaceutical R&D while also entering the Oregon
State market with additional markets to follow as legislation allows. As well,
Allied is in the process of applying for a Section 56 exemption in Canada for
Allied’s Physician group to be able to prescribe Allied’s formulation to
veterans and first responders. With this infrastructure in place, Allied will
be able to be one of the first companies to come to market in the psilocybin
space with both psilocybin products augmented by Allied’s current natural
health and cannabis-derived pharma products.
Pure
Extracts Technologies Corp. (CSE:
PULL) announced that it
is commencing a study on the formulation and manufacturing of psilocybin based
active treatments for oral tablets, capsules and a nasal gel that will be used
as an investigational product. The study with be conducted at the Toronto
Institute of Pharmaceutical Technology (“TIPT”) by Dr. Alexander MacGregor, a
key scientific advisor to the Company.
The study will focus on formulating,
manufacturing and clinical bioavailability testing of rapid onset psilocybin
dosage forms that could be used in future efficacy clinical trials by both Pure
Extracts and its pharmaceutical customers. Clinical batch manufacturing,
packaging and labelling are all included in the study as is conformity testing
and stability testing (including both long-term and accelerated). The study will
conform to both Canadian Good Manufacturing Practice (“GMP”) and Good Clinical
Practice (“GCP”) standards.
Dr. MacGregor is a pharmaceutical
science inventor, an expert in pharmaceutical technology and novel drug
delivery systems. He is a recipient of several global patents in the field of
medical treatments and pharmaceutical drug delivery technologies most notably
from Canada, US, Australia, Europe, Latin America, China, India and Japan. Dr.
MacGregor’s inventions have led to groundbreaking therapeutic drugs for the
treatment of cancer, management of diabetes, systemic infections and
post-operative pain. His company has a Health Canada Drug Establishment
License, a Cannabis Drug License and a Dealer’s License issued under the
Controlled Drugs and Substances Act (CDSA) and is thus licensed to possess
psychedelic drug compounds.
Pure Extracts CEO, Ben Nikolaevsky,
remarked, “Having the support of TIPT, one of Canada’s premiere pharmaceutical
R&D companies, while waiting to receive our Dealer’s License from Health
Canada is invaluable. We are very excited to be laying the groundwork for our
move into the controlled substances world of psychedelics and to be furthering
our knowledge-base in psilocybin and associated novel delivery mechanisms.”
Nova
Mentis Life Science Corp. (CSE:
NOVA) (OTC:
LIBFF)
announced that it
has added two additional psychedelic compounds to its drug portfolio. NOVA has
contracted with its U.S. partner to begin manufacturing the active
pharmaceutical ingredients (API), baeocystin and aeruginascin. NOVA is
currently developing C-GMP API psilocybin at its U.S. partner's facility which
has highly trained quality control staff on site and certifies all release
testing prior to human studies. Per contractual agreements, NOVA has ownership
of the API Drug Master Files ("DMF's"), which will be used for
regulatory submission prior to commencing human clinical trials.
"The availability of greater
than 95 per cent pure synthetic psilocybin, baeocystin and aeruginascin will
allow the creation of unique combinatory formulations with potential
therapeutic applications to various subsets of ASD," stated Marvin S.
Hausman MD, Chairman of NOVA's Scientific Advisory Board. "Furthermore,
the availability of these compounds will allow our collaborative scientific
chemists to develop technology to deliver our proprietary formulations to organ
systems outside of the brain. Are there tryptamine related therapeutic
receptors in the small intestine, colon and liver that need to be
discovered?"
Baeocystin is an analog of
psilocybin and is found in most psilocybin mushrooms along with other minor
tryptamine derivatives. Aeruginascin is also a tryptamine derivative and an
analog of psilocybin, but it occurs naturally within a different mushroom,
Inocybe aeruginascens. The pharmacological effects of both of these compounds
are not well understood and anecdotal usage reports reveal different euphoric
experiences.
It is theorized that psilocybin and
mushroom tryptamine derivatives, such as baeocystin and aeruginascin, when
utilized in concert, may produce what is referred to as an "entourage
effect". This theory was proposed for cannabis compounds but essentially
is applicable to other compounds within natural foods that work together to
create unique effects and benefits.
Pending final production of the
additional API compounds, NOVA plans to test their efficacy and potential
"entourage effect" related therapeutic benefits in the autism
spectrum disorder (ASD) preclinical rat model that was designed by Dr. Viviana
Trezza at Roma Tre University, Rome, Italy.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade
these stocks and other ideas on our site using our list of top stock trading apps including
Robinhood, Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast and column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news,
articles, podcasts and
stock directory
Tuesday 29 December 2020
Monday 28 December 2020
Wednesday 23 December 2020
Tuesday 22 December 2020
Investor Ideas #Potcasts 510, #Cannabis News and #Stocks on the Move (TSX: $WEED.TO) (NASDAQ: $CGC) (TSX: $RIV.TO) (CSE: $HOLL.C) (TSX: $VFF.TO)
Investor Ideas #Potcasts
510, #Cannabis News and #Stocks on the Move (TSX: $WEED.TO) (NASDAQ: $CGC)
(TSX: $RIV.TO) (CSE: $HOLL.C) (TSX: $VFF.TO)
Delta, Kelowna, BC, December 22, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/122220-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/12221WEED-CGC-RIV-HOLL-VFF.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few private and public company
announcements.
Canopy
Growth Corporation (TSX:
WEED) (NASDAQ:
CGC)
announced that it
has entered into an arrangement agreement with its wholly-owned subsidiary The
Tweed Tree Lot Inc., Canopy Rivers Inc. (TSX:
RIV)
and its wholly-owned subsidiary Canopy Rivers Corporation pursuant to which
Canopy Growth will acquire certain assets from CRC, as set out below, in
exchange for cash, common shares in the capital of Canopy Growth and the
surrender of all shares in the capital of Canopy Rivers held by Canopy Growth
by way of a plan of arrangement under the Business
Corporations Act (Ontario).
"Canopy Rivers was established
in 2017 as a strategic investment vehicle for Canopy Growth, helping us pursue
key business opportunities including development of the Vert Mirabel greenhouse
which today is a very important component of our Canadian cannabis
operations," said David Klein, CEO, Canopy Growth. "With our new
strategy in place, it is appropriate for us to divest our interest in Canopy
Rivers to increase our focus as a company."
Pursuant to the Arrangement, Canopy
Growth will increase its fully-diluted conditional ownership in TerrAscend Corp.
("TerrAscend") from approximately 13% to approximately 21% through
the acquisition of (i) 19,445,285 exchangeable shares in the capital of
TerrAscend; (ii) 2,225,714 common share purchase warrants in the capital of
TerrAscend with an exercise price of $5.95 per share; (iii) 333,723 common
share purchase warrants in the capital of TerrAscend with an exercise price of
$6.49 per share; and (iv) a $13.2 million loan receivable owing by TerrAscend
Canada Inc. to CRC. The securities in the capital of TerrAscend are not
currently convertible or exercisable, and will not be convertible or
exercisable until federal laws in the United States with respect to marijuana
are amended.
Subject to certain rights of first
refusal, Canopy Growth will also acquire all of the common shares and Class A
preferred shares in the capital of Les Serres Vert Cannabis Inc. ("Vert
Mirabel") held by CRC, thereby increasing Canopy Growth's ownership of the
issued and outstanding common shares in the capital of Vert Mirabel from
approximately 41% to approximately 67%.
In addition, all of the obligations
of Tweed NB, a Fredericton, New Brunswick based subsidiary of Canopy Growth
that was recently closed, owing to CRC pursuant to a royalty agreement between
the parties will be terminated. The termination of the royalty agreement will
provide Canopy Growth with annual cash savings of approximately $2.9 million
per year over the balance of the 24-year term of the agreement.
Canopy Growth currently owns
36,468,318 Class B multiple voting shares ("MVS") and 15,223,938
Class A subordinate voting shares ("SVS") in the capital of Canopy
Rivers, which represent approximately a 27% ownership interest and 84% of the aggregate
voting rights of Canopy Rivers. Pursuant to the Arrangement, all of the MVS and
SVS held by Canopy Growth will be repurchased by Canopy Rivers for cancellation
on a cashless basis. Canopy Growth will not have any equity, debt or other
interest in Canopy Rivers following completion of the Arrangement.
As additional consideration for the
assets being transferred and the termination of the royalty agreement, Canopy
Growth will make a cash payment to CRC of $115 million and issue an aggregate
of 3,750,000 Canopy Growth Shares.
Hollister
Biosciences Inc. (CSE:
HOLL) (OTC:
HSTRF) a diversified cannabis branding company with products
in over 280 dispensaries throughout California, and over 80 dispensaries
throughout Arizona, announced the
launch of its 2nd fulfillment depot for its direct-to-consumer cannabis
delivery platform, Dreamy Delivery.
The Company soft launched Dreamy Delivery
to friends and family in the San Francisco Bay Area of Northern California, to
ensure a seamless customer experience in early Q4 of 2020. The Company has
expanded the Platform, with Dreamy now successfully delivering to legal
cannabis consumers in the San Francisco Bay Area of Northern California and now
Sacramento, California. The Company hopes to launch Dreamy in the Central Coast
of California by early Q1 of 2021 with the ultimate goal of delivering Cannabis
statewide.
Carl Saling, CEO of Hollister,
shared, "Very excited to have opened our 2nd direct to consumer delivery
depot in record time, allowing us to serve legal adults in the Sacramento Area.
This furthers our quest to be a dominate direct to consumer delivery platform
in California."
Pure
Sunfarms,
the wholly owned subsidiary of Village
Farms International (TSX:
VFF)
(NASDAQ:
VFF)
announced that their quality, B.C.-grown dried flower products
are now available to Canadian patients through a supply agreement with Medical
Cannabis by Shoppers Inc., a subsidiary of Shoppers Drug Mart Inc., one of
Canada’s leading health, beauty and convenience retailers. Medical consumers in
provinces and territories across Canada will now have access to Pure Sunfarms’
cannabis products, including 14g and 28g packs of dried flower.
The first of Pure Sunfarms’ cannabis
products available include five varieties of 28g packs, and assorted sizes of
signature strains Afghan Kush, White Rhino, Island Honey, Pink Kush, D. Bubba,
and Headband. Pre-roll, oil and vape offerings will become available to Medical
Cannabis by Shoppers patients in early 2021.
Registered patients across Canada
can now purchase Pure Sunfarms’ products through the Medical Cannabis by
Shoppers marketplace, the largest national platform providing medical consumers
with convenient, one-stop access to a broad assortment of safe, high-quality
products to meet their medical cannabis needs. A dedicated team of
cannabis-trained advisors and Pharmacists are available by phone or email for
those patients who require guidance and support.
“This agreement is a big milestone
for Pure Sunfarms as the leading producer of B.C.-grown cannabis products in Canada.
This marks the first time medical patients in all provinces and territories
will have access to the widest selection of our dried flower products,” said
Mandesh Dosanjh, President & CEO, Pure Sunfarms. “We’re thrilled to partner
with the Medical Cannabis by Shoppers team, to offer consumers more choice and
access to our products as the medical space evolves and grows in Canada.”
MagicMed
Industries Inc. announced
today that it has completed the establishment of the
psilocybin-derivatives patent portfolio of the PsybraryTM and the launch of the
Candidate Selection program. The
PsybraryTM is a proprietary physical and knowledgebase collection of novel
psychedelic-derivative drug candidates, manufacturing methods, pharmacological
data, and patent filings that protect all of the above.
MagicMed's Chief Scientific Officer,
Dr. Peter Facchini, stated "Our psilocybin-derivatives portfolio, which
also captures dimethyltryptamine (DMT) derivatives, now includes 12 filed
patent applications directed to 9 different chemical compound categories
covering over 125 million individual molecules.
While we certainly don't expect to synthesize all of these molecules
during the development of new drug candidates, I am pleased to announce that,
as of today's launch of the Candidate Selection program, we have already
synthesized more than 100 distinct psilocybin-derivative drug candidates in our
state-of-the-art research and development facilities".
MagicMed's Intellectual Property
Advisor, Dr. Harm Deckers, continued, "Filing this broad portfolio of
patent applications is an important moment for the Company. Now that these patent applications claiming
composition, manufacture, and methods of use are on file with the U.S. Patent
and Trademark Office, international patent treaties prevent worldwide the
issuance of claims to other parties, should any file patent applications in the
future on any of these 125 million molecules".
Mental illness is a ubiquitous human
experience and an insufficiently addressed medical need. Psychedelic-associated
therapies offer an alternative to ineffective treatments, yet the
psychedelic-based drugs themselves require improvement to achieve reduced side
effects, better efficacy, and broader patient access. The mission of MagicMed
is to develop the PsybraryTM to deliver such much needed improved drug candidates
to its biotechnology and pharmaceutical partners.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Investors can trade these stocks and other ideas on our site using
our list of top
stock trading apps including Robinhood, Acorn, Stash and
others.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Subscribe to:
Posts (Atom)
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...